阿尔茨海默病血液星形胶质细胞生物标志物:系统综述与Meta分析
该系统综述与Meta分析检索至2023年3月23日,纳入36项研究(AD连续谱3366例,认知正常对照4115例),比较血液GFAP、YKL-40和S100B水平。AD连续谱患者GFAP与YKL-40高于认知正常者,且随疾病阶段进展进一步升高,S100B无显著差异。
要点
- AD连续谱患者血液GFAP和YKL-40水平高于认知正常者
- AD痴呆较AD所致MCI的GFAP和YKL-40水平更高
- 血液S100B水平在各组间无显著差异
核心结论
- AD连续谱患者血液GFAP和YKL-40水平较认知正常者显著升高,且在AD临床谱内与更晚期疾病阶段相关,作者认为两者反映AD相关病理。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE和Web of Science(2023年3月23日),不限语言、时间或研究设计,纳入36项研究(AD连续谱n=3366,认知正常n=4115),采用随机效应模型Hedge g法合并效应量,PROSPERO注册号CRD42023458305。
主要发现
- AD连续谱较认知正常者GFAP效应量1.15(95%CI 0.94-1.36,p<0.0001),YKL-40效应量0.38(95%CI 0.28-0.49,p<0.0001)。
- AD痴呆较AD所致MCI:GFAP效应量0.48(95%CI 0.19-0.76,p=0.0009),YKL-40效应量0.34(95%CI 0.10-0.57,p=0.0048)。
- 血液S100B水平未见显著差异。
- 未发现高风险偏倚研究。
关键数值与推荐
- AD诊断基于既定诊断标准和/或多学科临床共识;排除报告间接标志物指标(如标志物自身抗体水平)的研究。
- 偏倚风险评估采用修订版诊断准确性研究质量评估工具。
临床怎么用
- 作者认为血液GFAP和YKL-40反映AD相关病理;原文未据此给出临床推荐。
局限性
- 所Meta分析的研究人群缺乏文化和语言多样性。
- 作者指出未来需使用生物标志物定义AD人群的Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Neuroinflammation, particularly early astrocyte reactivity, is a significant driver of Alzheimer disease (AD) pathogenesis. It is unclear how the levels of astrocyte biomarkers change in patients across the AD continuum and which best reflect AD-related change. We performed a systematic review and meta-analysis of 3 blood astrocyte biomarkers (glial fibrillary acidic protein [GFAP], chitinase-3-like protein 1 [YKL-40], and S100B) in patients clinically diagnosed with AD. METHODS: MEDLINE and Web of Science were searched on March 23, 2023, without restrictions on language, time, or study design, for studies reporting blood levels of the astrocyte biomarkers GFAP, YKL-40, or S100B in patients on the AD continuum (including those with mild cognitive impairment [MCI] and dementia) and a cognitively unimpaired (CU) control population. AD diagnosis was based on established diagnostic criteria and/or comprehensive multidisciplinary clinical consensus. Studies reporting indirect biomarker measures (e.g., levels of biomarker autoantibodies) were excluded. Risk of bias assessment was performed using the revised Quality Assessment of Diagnostic Accuracy Studies tool. Pooled effect sizes were determined using the Hedge g method with a random-effects model. The review was prospectively registered on PROSPERO (registration number CRD42023458305). RESULTS: The search identified 1,186 studies; 36 met inclusion criteria (AD continuum n = 3,366, CU n = 4,115). No study was assessed to have a high risk of bias. Compared with CU individuals, patients on the AD continuum had higher GFAP and YKL-40 levels (GFAP effect size 1.15, 95% CI 0.94-1.36, p < 0.0001; YKL-40 effect size 0.38, 95% CI 0.28-0.49, p < 0.0001). Both biomarkers were elevated in more advanced clinical stages of the disease (i.e., in AD dementia compared with MCI due to AD: GFAP effect size 0.48, 95% CI 0.19-0.76, p = 0.0009; YKL-40 effect size 0.34, 95% CI 0.10-0.57, p = 0.0048). No significant differences in blood S100B levels were identified. DISCUSSION: We demonstrated significant elevations in blood GFAP and YKL-40 levels in patients on the AD continuum compared with CU individuals. Furthermore, within the AD clinical spectrum, significant elevation correlated with more advanced disease stage. Our findings suggest that both biomarkers reflect AD-related pathology. Our findings are limited by the lack of cultural and linguistic diversity in the study populations meta-analyzed. Future meta-analyses using a biomarker-defined AD population are warranted.
引用
- Holper S, Loveland P, Churilov L, et al. Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis. Neurology. 2024. PMID: 38986050. doi:10.1212/WNL.0000000000209537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。